Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ahmet Sevindik
A major local pharmaceutical industry group in Turkey is leading the formation of a new biotechnology platform that will focus on lobbying the government to create a more friendly investment environment, and promote joint projects and training. Given ongoing official moves to attract investments in the pharma and biotech field, the initiative appears to align well with broader existing policies.
Turkey's public health care payor has increased reimbursement prices of over 160 medical devices, the first time in almost 10 years. It has also eased the reimbursement process for patients to increase their access to medical products.
As Turkey’s City Hospitals project goes underway, with the first few hospitals already up and running, big medtech players are swooping down to capitalize on this opportunity which promise to boost the Turkish market by up to TRY2bn. However, intense competition, as well as basic problems that had been plaguing companies operating in that country, persists and still needs to be resolved.
Siemens Healthineers last month won a five-year contract to oversee the clinical lab service operations for two new hospitals in Turkey. The deal, expected to bring in at least €30m in revenue for Siemens, is part of Turkey's initiative to boost its health care system by modernizing existing, as well as building brand new facilities. Sevket On, General Manager of Siemens Healthineers Turkey, provides more insight into this deal as well as the group's broader strategies to capitalize on the growth opportunities presented by Turkey's health care expansion plans.
Turkey has been working on a new draft guide to increase access to orphan drugs, focusing on accelerating licensing procedures, and other incentives.
Turkey’s public payer body has said it will halt reimbursement of 54 products from 2018 unless manufacturers, including several multinationals, agree to start local production within a year.